Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BTMD Stock Forecast 2026-2027
$2.25
Current Price
$79.99M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to BTMD Price Targets
+77.8%
To High Target of $4.00
+33.3%
To Median Target of $3.00
-11.1%
To Low Target of $2.00
BTMD Price Momentum
+1.8%
1 Week Change
+14.2%
1 Month Change
-43.5%
1 Year Change
-13.5%
Year-to-Date Change
-52.6%
From 52W High of $4.75
+77.2%
From 52W Low of $1.27
📊 TOP ANALYST CALLS
Did BTMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Biote is one of their latest high-conviction picks.
Latest BTMD Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, BTMD has a bullish consensus with a median price target of $3.00 (ranging from $2.00 to $4.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $2.25, the median forecast implies a 33.3% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gregory Fraser at Truist Securities, projecting a 77.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BTMD Analyst Ratings
4
Buy
1
Hold
0
Sell
BTMD Price Target Range
Low
$2.00
Average
$3.00
High
$4.00
Current: $2.25
Latest BTMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BTMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2026 | Truist Securities | Gregory Fraser | Buy | Maintains | $4.00 |
| Mar 12, 2026 | B. Riley Securities | Neutral | Maintains | $N/A | |
| Mar 12, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Aug 7, 2025 | B. Riley Securities | Neutral | Downgrade | $N/A | |
| Mar 13, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Dec 16, 2024 | Craig-Hallum | Buy | Initiates | $N/A | |
| Mar 13, 2024 | Roth MKM | Buy | Reiterates | $N/A | |
| Feb 20, 2024 | B. Riley Securities | Buy | Initiates | $N/A | |
| Feb 1, 2024 | Jefferies | Buy | Initiates | $N/A | |
| Jan 18, 2024 | Truist Securities | Buy | Maintains | $N/A | |
| Jan 18, 2024 | Roth MKM | Buy | Maintains | $N/A | |
| Aug 15, 2023 | TD Cowen | Outperform | Maintains | $N/A | |
| Aug 14, 2023 | Roth MKM | Buy | Reiterates | $N/A | |
| Mar 30, 2023 | Roth MKM | Buy | Maintains | $N/A | |
| Sep 27, 2022 | Truist Securities | Buy | Initiates | $N/A | |
| Jun 24, 2022 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Jun 23, 2022 | Roth Capital | Buy | Initiates | $N/A |
Biote Corp. (BTMD) Competitors
The following stocks are similar to Biote based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biote Corp. (BTMD) Financial Data
Biote Corp. has a market capitalization of $79.99M with a P/E ratio of 5.2x. The company generates $188.16M in trailing twelve-month revenue with a 8.3% profit margin.
Revenue growth is -8.3% quarter-over-quarter, while maintaining an operating margin of +9.8% and return on equity of -53.7%.
Valuation Metrics
Market Cap
$79.99M
Enterprise Value
$185.85M
P/E Ratio
5.2x
PEG Ratio
-0.1x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-8.3%
Gross Margin
+68.9%
Operating Margin
+9.8%
Net Margin
+8.3%
EPS Growth
-83.4%
Financial Health
Cash/Price Ratio
+7.8%
Current Ratio
1.3x
Debt/Equity
-2.3x
ROE
-53.7%
ROA
+17.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biote Corp. (BTMD) Business Model
About Biote Corp.
What They Do
Healthcare company specializing in hormone optimization.
Business Model
The company operates a practice-building platform called the Biote Method, which provides certified practitioners with essential tools including education, training, software, and marketing support to deliver bioidentical hormone replacement therapy. Biote Corp. generates revenue through the sale of dietary supplements and sterile pellet insertion kits, as well as through service fees from healthcare providers utilizing their platform.
Additional Information
Founded in 2012 and based in Irving, Texas, Biote Corp. is positioned in the growing preventive healthcare market, focusing on personalized hormone therapy programs. The company's model empowers healthcare providers to address hormonal imbalances and promote wellness in patients, tapping into the increasing demand for hormone optimization solutions.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
223
CEO
Mr. Bret Christensen
Country
United States
IPO Year
2022
Website
www.biote.comBiote Corp. (BTMD) Latest News & Analysis
Latest News
Quick Summary
Biote Corp. (NASDAQ: BTMD) appointed Dr. Komal Bajaj as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is an experienced OB/GYN and reproductive geneticist.
Why It Matters
The appointment of Dr. Komal Bajaj as Chief Medical Officer enhances Biote's leadership with her extensive experience, potentially boosting investor confidence in the company's strategic direction and growth.
Source: Business Wire
Market Sentiment:
Neutral
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
19 days ago
Quick Summary
Biote (NASDAQ: BTMD) announced Bob Peterson as Interim CEO effective June 8, 2026, following Bret Christensen's resignation as CEO. Christensen will remain on the Board of Directors.
Why It Matters
Leadership changes can impact company strategy and stock performance. Bob Peterson's new role may influence investor confidence and future company direction at Biote.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Biote Corp. (BTMD) held its Q1 2026 earnings call, discussing financial performance and future outlook. Specifics on revenue and key metrics were not provided in the excerpt.
Why It Matters
The Q1 2026 earnings call for biote Corp. (BTMD) provides insights into financial performance, growth prospects, and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Biote (NASDAQ: BTMD) reported its Q1 2026 financial results, highlighting progress in strategic priorities and a focus on restoring sustainable procedure revenue growth.
Why It Matters
Biote's Q1 2026 results signal ongoing efforts to boost revenue growth, indicating potential for future profitability and investment opportunities in the hormone optimization market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Biote Corp. (BTMD) reported quarterly earnings of $0.06 per share, below the Zacks Consensus Estimate of $0.09 and down from $0.08 per share year-over-year.
Why It Matters
Biote Corp.'s earnings miss may signal operational challenges, potentially impacting stock performance and investor confidence in future growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Biote Corp. (Nasdaq: BTMD) will release its Q1 financial results on May 6, 2026, after market close, followed by a conference call at 5:00 p.m. ET.
Why It Matters
Biote Corp's upcoming financial results and conference call on May 6, 2026, are critical for assessing its performance and future growth potential in hormone optimization, impacting investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BTMD Stock
What is Biote Corp.'s (BTMD) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Biote Corp. (BTMD) has a median price target of $3.00. The highest price target is $4.00 and the lowest is $2.00.
Is BTMD stock a good investment in 2026?
According to current analyst ratings, BTMD has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BTMD stock?
Wall Street analysts predict BTMD stock could reach $3.00 in the next 12 months. This represents a 33.3% increase from the current price of $2.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biote Corp.'s business model?
The company operates a practice-building platform called the Biote Method, which provides certified practitioners with essential tools including education, training, software, and marketing support to deliver bioidentical hormone replacement therapy. Biote Corp. generates revenue through the sale of dietary supplements and sterile pellet insertion kits, as well as through service fees from healthcare providers utilizing their platform.
What is the highest forecasted price for BTMD Biote Corp.?
The highest price target for BTMD is $4.00 from Gregory Fraser at Truist Securities, which represents a 77.8% increase from the current price of $2.25.
What is the lowest forecasted price for BTMD Biote Corp.?
The lowest price target for BTMD is $2.00 from at , which represents a -11.1% decrease from the current price of $2.25.
What is the overall BTMD consensus from analysts for Biote Corp.?
The overall analyst consensus for BTMD is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are BTMD stock price projections?
Stock price projections, including those for Biote Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 11:44 AM UTC